IRCT2014092912789N7已完成3 期
A clinical trial to compare the effects of acarbose and metforminuse on ovulation induction success in women with polycystic ovary syndrome
Vice Chancellor for Research, Kurdistan University of Medical Sciences0 个研究点目标入组 60 人开始时间: 待定最近更新:
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 60
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20 years 至 40 years（—）
- 性别
- Female
入选标准
- •age 20-40 years, women with polycystic ovary syndrome diagnosed by the rotterdam consensus criteria.
- •Exclusion criteria: Smoking, Cushing's syndrome, thyroid function disorders, androgen secreting tumors, patients with liver disease, kidney disease, heart disease, diabetes, and use of other drugs for polycystic ovary syndrome.
排除标准
- 未提供
研究者
相似试验
已完成
2 期
Investigating the effect of Albumin on urine output, using it with lasix and mannitol in ICU patients with oliguriaAcute renal failure.Acute renal failure, unspecifiedIRCT2016013010741N3Vice chancellor for research, Kerman University of Medical Sciences100
进行中（未招募）
不适用
Evaluation of optimal treatment combination of bevacizumab in combination with gemcitabine/carboplatin or pegylated liposomal doxorubicin/carboplatin in patients with platin-sensitive recurrent ovarian cancer.Evaluation of the best therapeutic index for patients with platinum-sensitive ovarian cancer when treatment with bevacizumab and gemcitabine/carboplatin or with bevacizumab and PLD/carboplatin.MedDRA version: 18.1Level: PTClassification code 10016180Term: Fallopian tube cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 18.1Level: PTClassification code 10066697Term: Ovarian cancer recurrentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2012-004125-24-BEAGO Research GmbH654
进行中（未招募）
1 期
Evaluation of optimal treatment combination of bevacizumab in combination with gemcitabine/carboplatin or pegylated liposomal doxorubicin/carboplatin in patients with platin-sensitive recurrent ovarian cancer.EUCTR2012-004125-24-DEAGO Research GmbH654
进行中（未招募）
1 期
Evaluation of optimal treatment combination of bevacizumab in combination with gemcitabine/carboplatin or pegylated liposomal doxorubicin/carboplatin in patients with platin-sensitive recurrent ovarian cancer.Evaluation of the best therapeutic index for patients with platinum-sensitive ovarian cancer when treatment with bevacizumab and gemcitabine/carboplatin or with bevacizumab and PLD/carboplatin.MedDRA version: 18.0Level: PTClassification code 10016180Term: Fallopian tube cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 18.0Level: PTClassification code 10066697Term: Ovarian cancer recurrentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2012-004125-24-ATAGO Research GmbH654
已完成
不适用
A clinical trial for efficacy and safety onCarbon-ion re-irradiation for locally recurrent pancreatic cancer in patients with prior carbon-ion radiotherapyPancreatic CancerJPRN-UMIN000026541ational Institutes of Quantum and Radiological Science and Technology24